Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- blistering skin lesions
Otros factores de diagnóstico
- skin hyperpigmentation
- hypertrichosis
- scarring alopecia
- red urine
Factores de riesgo
- male, middle-aged, white people
- alcohol use
- smoking
- estrogen therapy
- hepatitis C
- HIV
- hereditary hemochromatosis gene (HFE) mutation
- uroporphyrinogen decarboxylase (UROD) mutations
- exposure to halogenated polycyclic aromatic hydrocarbons
- reduced levels of antioxidants
- end-stage renal disease
- diabetes mellitus
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- plasma total porphyrins
- plasma fluorescence emission
- urinary total porphyrins
- erythrocyte total porphyrins
Pruebas diagnósticas que deben considerarse
- fractionation of plasma porphyrins by high-performance liquid chromatography (HPLC)
- fractionation of urinary porphyrins by HPLC
- erythrocyte uroporphyrinogen decarboxylase (UROD) activity
- fecal porphyrins
- DNA studies
- Liver function tests
- serum ferritin
- liver biopsy
- skin biopsy
- serum HIV enzyme-linked immunosorbent assay
- serum hepatitis C surface antibodies
- creatinine
- BUN
- hematocrit
- hemoglobin
Algoritmo de tratamiento
no phlebotomy contraindications
phlebotomy contraindicated or poorly tolerated
relapse after remission
Colaboradores
Autores
Gagan Sood, MD
Associate Professor
Department of Medicine and Surgery
Baylor College of Medicine
Houston
TX
Divulgaciones
GS is an author of a number of references cited in this topic.
Karl E. Anderson, MD
Professor
Departments of Preventive Medicine and Community Health and Internal Medicine
University of Texas Medical Branch
Galveston
TX
Divulgaciones
KEA has received grants from the National Institutes of Health, the US Food and Drug Administration, and Alnylam Pharmaceuticals; he is an author of a number of references cited in this topic. KEA has received consulting fees, advisory board fees, and grants to the university from Alnylam Pharmaceuticals; consulting fees, advisory board fees, and grants from Recordati Rare Diseases; and consulting fees and grants from Mitsubishi Tanabe Pharma America.
Revisores por pares
Robert S. Dawe, MBChB, MRCP(UK), MD(Glasgow)
Consultant Dermatologist
Honorary Clinical Senior Lecturer
Department of Dermatology
Ninewells Hospital & Medical School
Dundee
UK
Divulgaciones
RSD declares that he has no competing interests.
Jeffrey P. Callen, MD
Professor of Medicine (Dermatology)
University of Louisville
Louisville
KY
Divulgaciones
JPC declares that he has no competing interests.
Montgomery Bissell, MD
Professor and Chief
Gastroenterology
University of California
San Francisco
CA
Divulgaciones
MB declares that he has no competing interests.
Referencias
Artículos principales
Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA. 2007 Jan;104:5079-84.Texto completo Resumen
Jalil S, Grady JJ, Lee C, et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2010 Mar;8(3):297-302;e1.Texto completo Resumen
Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019 Nov;128(3):271-81. Resumen
Handler NS, Handler MZ, Stephany MP, et al. Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol. 2017 Jun;56(6):e106-17. Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Variegate porphyria (VP)
- Hereditary coproporphyria (HCP)
- Congenital erythropoietic porphyria (CEP)
Más DiferencialesInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad